Skip to main content
. Author manuscript; available in PMC: 2019 Nov 29.
Published in final edited form as: Nature. 2019 May 29;570(7761):385–389. doi: 10.1038/s41586-019-1272-6

Fig. 1. Schematic of DELFI approach.

Fig. 1.

Blood is collected from healthy individuals and patients with cancer. cfDNA is extracted from plasma, processed into sequencing libraries, examined through WGS, mapped to the genome, and analyzed to determine cfDNA fragmentation profiles across the genome. Machine learning is used to categorize whether individuals have cancer and identify tumor tissue of origin.